NICE reverses rejection of Celgene's Revlimid
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has made a U-turn on its decision regarding Celgene's Revlimid (lenalidomide) in myelodysplastic syndromes, recommending the drug in final draft guidance.